A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF Genotypes

  • STATUS
    Recruiting
  • End date
    May 19, 2021
  • participants needed
    108
  • sponsor
    Vertex Pharmaceuticals Incorporated
Updated on 23 December 2020
Investigator
Medical Monitor
Primary Contact
Centre de Perharidy (0.0 mi away) Contact
+32 other location
fibrosis
forced expiratory volume
ivacaftor
tezacaftor
elexacaftor

Summary

This study will evaluate the efficacy and safety of elexacaftor (ELX) / tezacaftor (TEZ) / ivacaftor (IVA) triple combination (TC) in subjects 6 through 11 years of age with cystic fibrosis (CF) who are heterozygous for F508del and a minimal function (MF) mutation (F/MF genotypes).

Details
Treatment Placebo, IVA, ELX/TEZ/IVA
Clinical Study IdentifierNCT04353817
SponsorVertex Pharmaceuticals Incorporated
Last Modified on23 December 2020

Adding a note
adding personal notes guide

Select a piece of text and start making personal notes.

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study

user name

Annotated by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No made yet